ethambutol,

Ethambutol, (R, R)- can be used to treat tuberculosis. It is usually used in combination with other tuberculosis medications. It may also be used to treat Mycobacterium avium complex, and Mycobacterium kansasii.

Ethambutol dihydrochloride is an anti-mycobacterial compound that inhibits arabinosyl transferase activity to prevent cell wall formation and can be used to induce hyperuricemia models.

Ethambutol is an oral anti-tuberculosis drug that inhibits arabinosyl transferase activity, thereby interfering with the synthesis of arabinogalactan and preventing cell wall formation to exert its antibacterial effect; it can also be used for animal models of hyperuricemia and optic neuropathy.

Ethambutol.2HCl-d4 is a deuterated compound of Ethambutol.2HCl.

Ethambutol-d8 is a deuterated compound of Ethambutol. Ethambutol has a CAS number of 74-55-5. Ethambutol is a bacteriostatic antimycobacterial agent obstructed the formation of cell wall by inhibiting arabinosyl transferases.

Ethambutol-KLH is an antigen-adjuvant conjugate consisting of Ethambutol linked with keyhole limpet hemocyanin (KLH). By conjugating the antigen with a protein adjuvant, it strengthens the production of antigen-specific antibodies in vaccine models. The conjugate does not affect protein folding or disrupt primary epitopes and enhances cross-presentation and the generation of antigen-specific T cells.

Ethambutol-BSA is an antigen-adjuvant conjugate of Ethambutol and bovine serum albumin (BSA). Conjugating the antigen with a protein adjuvant can enhance the production of antigen-specific antibodies in vaccine models. The conjugate does not affect protein folding or disrupt major epitopes, while enhancing cross-presentation and the production of antigen-specific T cells.

OPC-167832 is a potent and orally active dprE1 Inhibitor with an IC50 of 0.258 μM. OPC-167832 has antituberculosis activity and can be used for the research of tuberculosis caused by Mycobacterium tuberculosis[1]. OPC-167832 exhibits very low MICs against laboratory strains of M. tuberculosis H37Rv (MIC: 0.0005 μg/ml) and Kurono (MIC: 0.0005 μg/ml) and strains with monoresistance to rifampin (RIF), isoniazid (INH), ethambutol (EMB), streptomycin (STR), and pyrazinamide (PZA) (MIC: 0.00024-0.001 μg/ml). However, OPC-167832 has minimal or no activity against standard strains of nonmycobacterial aerobic and anaerobic bacteria[1].The IC90 values of OPC-167832 against intracellular M. tuberculosis strains H37Rv and Kurono are 0.0048 and 0.0027 μg/ml, respectively. OPC-167832 shows bactericidal activity against intracellular M. tuberculosis at a low concentration, and the bactericidal activity is saturated at concentrations of 0.004 μg/ml or higher[1]. OPC-167832 (oral administration; 0.625-10 mg/kg) exhibits a good pharmacokinetic characteristic. The plasma reaches peak at 0.5 h to 1.0 h (tmax) and is eliminated with a half-life (t1/2) of 1.3 h to 2.1 h OPC-167832 distribution in the lungs is approximately 2 times higher than that in plasma, and the Cmax and AUCt of OPC-167832 in plasma and the lungs shows dose dependency[1].OPC-167832 (oral administration; 0.625-10 mg/kg; 4 weeks) significantly reduces lung CFU compared to the vehicle group. The dose-dependent decrease of lung CFU is observed from 0.625 mg/kg to 2.5 mg/kg. In a M. tuberculosis Kurono-infected ICR female mice model. OPC-167832 combines with DMD, BDQ, or LVX via oral gavage exhibits significantly higher efficacies than each single agent alone[1].[1].OPC-167832 (oral gavage; 2.5 mg/kg; combination with DCMB; 12 weeks) demonstrates the most potent efficacy when compares with DC, DCB. The lung CFU count after 6 weeks of treatment is below the detection limit, and at the end of just 8 weeks of treatment, the bacteria in the lungs of all the evaluated mice had already been eradicate[1]. [1]. Norimitsu Hariguchi, et al. OPC-167832, a Novel Carbostyril Derivative with Potent Antituberculosis Activity as a DprE1 Inhibitor.Antimicrob Agents Chemother. 2020 May 21;64(6):e02020-19.